Member Info for KingHomerJ

The reality is what it is…..

The market cap is x10 below what it should be and has been for a while.

The research papers that I’ve previously posted are what they are…..also we’re not cheap (lol)

Take it or leave it……

Precision Dosing Tool – Multi-Million Revenue Potential

Physiomics’ precision dosing technology, developed in partnership with Beyond Blood Diagnostics, NHS Blackpool and DoseMeRx, represents one of the company’s most significant long-term value drivers.

Unlike traditional consultancy revenue, this is a scalable, recurring, software-driven product with global distribution through DoseMeRx, which is already deployed across hospitals and healthcare systems worldwide.

Once fully validated and commercialised, the dosing tool can be licensed per hospital, per department, or per clinician, creating a high-margin, repeat-revenue model rather than one-off service fees.

Comparable Example

A close comparator is DoseMeRx itself and other clinical decision-support platforms such as InsightRX (precision dosing software used by hospitals for drug optimisation). These platforms operate on subscription models that can generate multi-million annual revenues through hospital licensing and per-patient usage fees.

With even modest adoption — for example:

• 500 hospitals globally

• at £10,000 per year per site

This would already represent £5 million per year in recurring revenue.

At larger scale, this figure can reasonably rise into the tens of millions annually, before accounting for expansion into additional drugs and indications.

Strategic Value

Because this product sits directly inside a global platform (DoseMeRx), Physiomics does not need to build a global sales force to scale — the route to market is already in place. This dramatically lowers commercial risk and increases the likelihood of rapid adoption.

This single asset alone has the potential to transform Physiomics from a niche consultancy into a high-margin healthcare software company, justifying a valuation many times higher than its current market capitalisation

GlobalData

Valuation Outlook: With continued execution, pipeline conversion, and commercialisation of its dosing platform, Physiomics is well positioned to justify a significantly higher market capitalisation — potentially into the tens of millions GBP — thereby closing the valuation gap to true business value.

GlobalData

B. NHS / Innovate UK-backed Projects

Projects such as PREDICT-ONC in partnership with Beyond Blood Diagnostics and Blackpool Teaching Hospitals NHS Foundation Trust are progressing validation of predictive tools using real patient data — a crucial clinical step before broad commercial rollout.

Bringing real clinical outcomes data back into development strengthens commercial traction, regulatory discussions, and future licensing or payer adoption.

Financial Position — Cash & Growth Outlook

Physiomics has:

• significantly increased contracted forward revenue, with nearly £594k contracted into the next fiscal year, up ~19% year-on-year.

• raised growth funding via oversubscribed placings to fuel sales, BD, and capability expansion.

• strong cash balances supported by fundraising early 2025 and improved operating performance (less loss and stronger revenue growth).

This paints a picture of a business that is carefully managing cash, investing in growth, and improving its sales pipeline — all supportive of future valuation uplift.

Valuation Opportunity & Strategic Optionality

A. Undervaluation Relative to Peers

Many comparable service-oriented CROs and specialised modelling players trade at multiples that imply market caps far above Physiomics’ current valuation, based on growth trajectory and recurring revenue potential.

Given pipeline conversion, recurring revenue from dosing software, and continued contract wins, re-rating to a market cap in the tens of millions GBP is justified with even modest growth assumptions.

B. Acquisition Interest & Strategic M&A Optionality

Physiomics’ capabilities — especially Virtual Tumour™, PK/PD modelling teams, biostatistics services, and DoseMeRx partnership — could be compelling as a bolt-on acquisition for larger CROs, pharma consultancies, or digital health firms looking to embed advanced simulation and personalised dosing technology into their offerings.

The highly technical nature of its services and proprietary tools makes it a strategic fit for larger players seeking niche but valuable intellectual assets. This optionality adds valuation upside beyond traditional revenue multiples.

Conclusion

Physiomics plc stands at the intersection of high-value drug development services, proprietary modelling technology, and next-generation personalised dosing tools — a combination that is under-appreciated in its current share price.

Key investment thesis points:

✔ Proven technology with proprietary differentiator in Virtual Tumour™.

✔ Established clients including global pharma and research organisations.

✔ Growing contracted revenue and diversified services.

✔ Strategic software partnership (DoseMeRx) with global reach.

✔ Clinical validation partnerships with NHS and Innovate funding.

✔ Significant upside relative to peers and M&A optionality.

Executive Summary

Physiomics plc (AIM: PYC) is uniquely positioned as a specialist modelling & simulation, PK/PD, QSP, data science and biostatistics consultancy serving biotech and pharmaceutical clients. The company has proprietary technology, an expanding client roster including global life-science names, growing contracted revenue, strategic partnerships in personalised medicine, and an industry-wide shift toward model-informed drug development — yet its market valuation lags materially behind peers and intrinsic value.

Core Business Strengths

Proprietary, High-Value Technologies

Physiomics’ Virtual Tumour™ platform is a proprietary modelling technology used to predict drug effects (particularly in oncology and combination therapies). This kind of platform is rare in small CROs and provides differentiated, defensible IP in a technical niche that is becoming central to drug development — a high-barrier asset that competitors do not replicate easily.

Strong Revenue Momentum & Expanding Services

• The company achieved record levels of contract wins in recent years with over £1m average annual pipeline wins.

• Modelling & Simulation revenue grew substantially (e.g., 44% year-on-year).

• Introduction of a Biostatistics/Statistical Programming service line broadens the addressable market and client utility.

These trends point to scalable core services, fee-for-service cash inflows, and repeat business, which are hallmarks of enterprise value.

Commercial Validation from High-Profile Clients

Physiomics’ client roster features established global players and innovative biotechs, providing both credibility and commercial stability:

Confirmed clients include:

• Merck KGaA (global pharmaceutical).

• Numab Therapeutics (clinical-stage biotech).

• Cancer Research UK (major nonprofit research organisation).

• Astellas, Bicycle Therapeutics.

Winning contracts from (and extensions with) these organisations indicate trusted delivery and deep technical relevance — a clear signal that expertise, not just price, defines the company’s work.

Strategic Growth Drivers Beyond Core Consultancy

A. Personalised Dosing Tool & DoseMe Partnership

Physiomics has integrated its dose-optimization software into DoseMeRx’s global platform (a leading clinician toolset), establishing a route to meaningful recurring revenue once fully commercialised.

This is more than a research collaboration — it bridges clinical use with market adoption, meaning the dosing tool alone could eventually become a revenue stream worth tens of millions GBP if uptake grows worldwide, given the reach and scale of DoseMeRx.

The company was at 16mil MC 4 years ago

Since then the company has increased ten fold with new revenue stream like the bio stats will produce more revenue that the current consultancy - why this is now a FDA legal requirement….the traction on the bio stats is massive and evidence showing PYC has a contract with GARDP foundation which was formed by the WHO

That’s before we even talk about the precision dosing tool currently intergrated into DoseMerx and has trials with beyond blood and NHS

Having followed Doc for years - he is very open if he takes placing and has taken placings with PYC previously

Therefore why has he purchased on open market !

As stated TR1 incoming.....

Id expect a TR1 in due course.....

Been advertised a while tbf

Rapidly Growing Pipeline.....

The Company recently expanded its contract services into the field of Biometrics, which is run as a separate service-line and provides biostatistics, statistical programming and data management solutions. Even though only recently launched, this service-line is already delivering on several client contracts and has a rapidly growing pipeline of opportunities being progressed.

Exactly…….

Contract Research Organisation

CRO.....

Expect a TR1 incoming.....

Likely more bio stats contracts in coming days / weeks

After speaking to the company numerous times directly - they are very confident & hopeful to release positive news on numerous fronts in the near near term - which will "truly show that the company is on a large growth trajectory, which will restore confidence in the Market"

After speaking to the company directly numerous times they are very confident on restoring market confidence via contract wins and truly show the growth.

I’d expect positive news on numerous fronts in the near near term.

It’s nailed on…

Huge Rerate

Trout....lets see what news arrives early 2026.

All the best

If the Physiomics dosing tool is successfully approved as a Software as a Medical Device (SaMD) after the PREDICT-ONC trial, its estimated value would transition from the current nominal value (linked to the company's sub-£1 million market cap) to a valuation potentially in the tens of millions of pounds, or even higher in a strategic acquisition scenario.

This potential valuation is based on applying standard HealthTech metrics and cost savings figures:

Valuation Breakdown:

Current Company Valuation: The entire Physiomics plc has a market capitalization of under £1 million. The tool's current value as an unapproved asset is a fraction of that.

Cost Savings Potential: The tool targets the reduction of costly febrile neutropenia (FN) hospitalizations, which cost around $25,000 USD (£20,000+) per event in the US and several thousand pounds in the UK. The value of a tool that can prevent these events is substantial to healthcare providers and insurers.

Revenue Model (Post-Approval): Upon approval, the company could shift to a scalable licensing or subscription model (Software as a Service - SaaS) with hospitals, EHR providers like Epic or Cerner, or major CROs.

Estimates from similar health tech suggest potential savings or revenue per patient of several thousand dollars annually.

Valuation Multiples: Precision medicine software companies often trade at high revenue multiples (4x to 8x+ revenue) because of their high growth potential and strategic value.

The estimated value would likely be in the range of £10 million to £50 million+ after successful validation and regulatory approval, depending heavily on market adoption and integration with major platforms.

Baseline Valuation: Based on potential recurring revenue in the early millions of pounds, a standard 4x-6x revenue multiple would place the value in the £4m to £12m range.

Strategic Acquisition Premium: For a large player like a major CRO (IQVIA, ICON) or a medtech giant (Siemens, Philips) seeking to integrate this functionality into their platforms, the strategic value of an approved, validated tool that standardizes care and de-risks trials could fetch a significant premium, pushing the value much higher, potentially into the £50m+ range.

GE HealthCare, for example, recently acquired a clinical AI software unit for up to $51 million.

The PREDICT-ONC trial is the key de-risking event that transitions the tool from an idea with potential to a quantifiable, valuable commercial asset.